Core Viewpoint - The company continues to experience high growth in performance and profitability, with significant increases in revenue and net profit in the first half of 2025 [1] Financial Performance - The company achieved revenue of 390 million yuan in the first half of 2025, representing a year-on-year growth of 29.4% [1] - The net profit attributable to the parent company was 80 million yuan, showing a year-on-year increase of 47.8% [1] Domestic and International Sales - Domestic sales revenue reached 120 million yuan, growing by 36.7% year-on-year [1] - International sales revenue was 260 million yuan, with a year-on-year growth of 22.9% [1] - The rapid growth in domestic sales is attributed to the recovery of the innovative drug market and increased efforts in new product development [1] Product Development and Market Expansion - The company is actively expanding its product and technical services in the ADC field, including various target proteins and enzymes for linker cleavage [1] Profit Forecast and Investment Recommendation - The company maintains its profit forecast, predicting net profits of 154 million yuan, 208 million yuan, and 253 million yuan for 2025-2027 [1] - Based on the average price-to-earnings ratio of comparable companies, a target price of 67.34 yuan is set for 2025, with a "buy" rating maintained [1]

Core Viewpoint - The company Baipusais (301080.SZ) has announced a significant reduction in shareholding by its shareholders, indicating a shift in ownership dynamics and potential implications for investor confidence [1] Group 1: Shareholding Changes - On September 10, 2025, Mr. Miao Jingyun reduced his shareholding by 206,100 shares through block trading [1] - An Yi Baipusais also reduced its shareholding by 500,000 shares through block trading, totaling a reduction of 706,100 shares [1] - This reduction accounts for 0.42% of the company's total share capital and 0.42% of the total shares excluding those in the repurchase account [1] Group 2: Control and Ownership - Following the share reduction, the actual controller and its concerted parties' combined shareholding decreased from 44.01% to 43.59% [1] - The proportion of shares held, excluding those in the repurchase account, decreased from 44.19% to 43.77% [1] - The change in combined shareholding has reached a threshold of 1% in terms of equity variation [1]

Core Viewpoint - The company Baipusais (301080.SZ) has announced a significant reduction in shareholding by its major shareholders, indicating a shift in ownership dynamics and potential implications for investor confidence [1] Shareholding Reduction - On September 10, 2025, Mr. Miao Jingyun reduced his holdings by 206,100 shares through block trading, while Anyi Baipusais reduced its holdings by 500,000 shares, totaling a reduction of 706,100 shares [1] - This reduction accounts for 0.42% of the company's total share capital and 0.42% of the total shares excluding those in the repurchase account [1] - Following this reduction, the actual controller and its concerted parties' shareholding percentage decreased from 44.01% to 43.59%, and from 44.19% to 43.77% when excluding repurchased shares [1]

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 证券代码：301080 证券简称：百普赛斯 公告编号：2025-059 北京百普赛斯生物科技股份有限公司 关于实际控制人之一致行动人减持股份触及 1%整数倍的公告 公司实际控制人之一致行动人苗景赟先生、安义百普赛斯企业管理 咨询合伙企业（有限合伙）、安义百普嘉乐企业管理咨询合伙企业（有 限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 14 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《关于实际控制 人之一致行动人及高级管理人员减持股份的预披露公告》（公告编号：2025-048）。 公司实际控制人陈宜顶先生的一致行动人苗景赟先生计划自 2025 年 9 月 5 日至 2025 年 12 月 4 日以集中竞价或大宗交易方式减持所持有的公司股份合计不超过 400,000 股（占公司总股本的 0.24%，占公司剔除回购专用账户中股份数量后股份 总数的 0.24%）。公司实际控制人陈宜顶先 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-060 北京百普赛斯生物科技股份有限公司 关于召开 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于召开 2025 年第三次临时股东大会的通知》（公告编号：2025-055），公司将于 2025 年 9 月 16 日（星期二）14:30 召开 2025 年第三次临时股东大会。本次股东 大会将采取现场投票和网络投票相结合的方式召开，根据相关规定，现将有 关事项再次提示如下： 一、召开会议的基本情况 5、会议的召开方式：现场表决与网络投票相结合的方式召开。 公 司 将 通 过 深 圳 证 券 交 易 所 交 易 系 统 和 互 联 网 投 票 系 统 （http://wltp.cninfo.com.cn）向公司全体股东提供网络形式的投票平台，公 司股东可以在网络投票时间内通过上述系统行使表决权。 公 ...

Group 1 - The stock price of Beijing Baipusi Biotechnology Co., Ltd. dropped by 5.15% to 57.67 CNY per share, with a total market capitalization of 9.68 billion CNY as of the report date [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - The fund "Lubo Mai China Medical Health Stock Initiation A" holds 15,700 shares of Baipusi, accounting for 3.84% of the fund's net value, making it the ninth largest holding [2] - The fund was established on December 26, 2023, with a current scale of 14.52 million CNY, achieving a year-to-date return of 44.16% and a one-year return of 58.26% [2] Group 3 - The fund manager of "Lubo Mai China Medical Health Stock Initiation A" is Li Tao, who has been in the position for 1 year and 261 days, with total assets under management of 29.25 million CNY [3] - During Li Tao's tenure, the best fund return was 17%, while the worst was 15.79% [3]

Summary of Key Points - On September 10, Baipusais received a 7.04% increase in stock price, closing at 60.80 yuan, with 11 block trades totaling 706,100 shares and a transaction amount of 37.6998 million yuan [1][2][3] - The first three block trades were executed at a price of 53.39 yuan per share, with a total of 7.5 million shares traded in the first transaction, amounting to 4.0043 million yuan, reflecting a premium rate of -12.19% [1][2] - The subsequent trades continued at the same price of 53.39 yuan, with varying volumes and transaction amounts, consistently showing a premium rate of -12.19% [2][3] - Over the last three months, the stock has recorded a total of 12 block trades, with a cumulative transaction amount of 57.9358 million yuan [3] - In the last five trading days, the stock has declined by 7.18%, with a net outflow of 44.093 million yuan in principal funds [3]

证券之星消息，9月9日生物制品板块较上一交易日下跌1.42%，百普赛斯领跌。当日上证指数报收于 3807.29，下跌0.51%。深证成指报收于12510.6，下跌1.23%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688331 | 荣昌生物 | 104.09 | 11.92% | 20.79万 | 21.93亿 | | 300357 | 我武生物 | 33.06 | 1.88% | 17.98万 | 5.9067 | | 688180 | 君实生物 | 48.26 | 1.54% | 26.84万 | 13.23 乙 | | 002581 | ST未名 | 7.71 | 1.18% | 7.66万 | 5908.98万 | | 836547 | 元锡晶海 | 30.34 | 0.40% | 2.62万 | 7882.88万 | | 600211 | 西藏药业 | 55.62 | 0.16% | 21.25万 | 11.86亿 | | 000403 | 派林生 ...

9月9日，百普赛斯跌5.05%，截至发稿，报57.40元/股，成交1.38亿元，换手率1.86%，总市值96.34亿 元。 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 从基金十大重仓股角度 数据显示，天弘基金旗下1只基金重仓百普赛斯。天弘医疗健康A（001558）二季度持有股数41.42万 股，占基金净值比例为5.9%，位居第七大重仓股。根据测算，今日浮亏损失约126.35万元。 天弘医疗健康A（001558）成立日期2015年6月30日，最新规模2.51亿。今年以来收益48.85%，同类排 名621/8179；近一年收益59.58%，同类排名1865/7984；成立以来收益87.36%。 天弘医疗健康A（001558）基金经理为吕俏。 截至发稿，吕俏累计任职时间251天，现任基金资产总规模5.02亿元，任职 ...

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 68.12 RMB based on a 2025 PE of 60X, which is slightly discounted compared to peers due to stable operations [5][9]. Core Insights - The company's revenue continues to grow rapidly, with domestic demand gradually recovering. The introduction of new products in the R&D pipeline is expected to open up additional demand opportunities [2][5]. - In the first half of 2025, the company achieved a revenue of 387 million RMB, representing a year-on-year increase of 29.38%. The net profit attributable to shareholders was 83.80 million RMB, up 47.81% [5][9]. - The domestic revenue reached 123 million RMB, reflecting a growth of 36.65%, while overseas revenue was 258 million RMB, increasing by 22.94% [5][9]. - The company has effectively controlled its expense ratios, leading to improved profitability. The gross profit margin for the first half of 2025 was 90.14%, and the net profit margin was 21.53%, an increase of 3.59 percentage points year-on-year [5][9]. Financial Summary - The financial summary indicates a strong growth trajectory, with total revenue projected to reach 840 million RMB in 2025, up 30.2% from the previous year. Net profit attributable to shareholders is expected to be 191 million RMB, a 53.9% increase [4][6]. - The company has increased its R&D investment, expanding its team to 279 personnel and diversifying its product offerings, with over 5000 products sold [5][9]. - The report highlights the successful development of nearly 50 GMP-grade products in the CGT field and a range of high-quality products in the ADC field [5][9].